Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973351 | 0.98 | HPGD (0.55) | HPGDALDH1A1USP2GAAMEN1 | |
| SCHEMBL1723442 | 0.81 | POLB (0.51) | HPGDALDH1A1CYP2C9 | |
| SCHEMBL2425734 | 0.79 | SIGMAR1 (0.61) | HPGDALDH1A1USP2MEN1KMT2A | |
| SCHEMBL11790594 | 0.79 | HPGD (0.55) | HPGDALDH1A1USP2GAAMEN1 | |
| SCHEMBL27798296 | 0.77 | HPGD (0.63) | HPGDALDH1A1USP2GAAMEN1 | |
| SCHEMBL2182275 | 0.77 | HPGD (0.63) | HPGDALDH1A1USP2GAAMEN1 | |
| SCHEMBL10777394 | 0.76 | ALDH1A1 (0.67) | HPGDALDH1A1GAAMEN1KMT2A | |
| SCHEMBL11475019 | 0.75 | HPGD (0.55) | HPGDALDH1A1USP2GAAMEN1 | |
| SCHEMBL8859075 | 0.75 | ALDH1A1 (0.60) | HPGDALDH1A1USP2GAAMEN1 | |
| SCHEMBL1927946 | 0.74 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | claimed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | claimed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | claimed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-8933076-B2 | Pyridazine compounds, compositions and methods | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2015-01-13 | — | — | US | disclosed |
| EP-2592075-A1 | Pyridazine compounds for the treatment of inflammatory diseases | Northwestern University (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| WO-2007130383-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES | NORTHWESTERN UNIVERSITY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007127475-A2 | PYRIDAZINES FOR DEMYELINATING DISEASES AND NEUROPATHIC PAIN | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127474-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1812408-A2 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | Northwestern University (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006050389-A2 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2006-05-11 | — | — | WO | disclosed |
| US-6143744-A | Sulfamide-metalloprotease inhibitors | SYNTEX (U.S.A.) INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6130220-A | ENZYME INHIBITORS | SYNTEX (USA) INC. (US) | 2000-10-10 | — | — | US | disclosed |
| US-5998412-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | SYNTEX (U.S.A.) INC. (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | HPGD 91/4885ALDH1A1 2748/4885USP2 3075/4885 |
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | HPGD 2384/4885ALDH1A1 323/4885USP2 2354/4885 |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | HPGD 91/4885ALDH1A1 2748/4885USP2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.